抗血管生成酪氨酸激酶抑制剂联合免疫检查点抑制剂治疗肉瘤药物安全管理共识  

Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors in combination with immune checkpoint inhibitors for sarcoma treatment

作　　者：无 

机构地区：[1]抗癌协会骨肿瘤与骨转移癌专业委员会

出　　处：《中国骨与关节杂志》2023年第5期374-380,共7页Chinese Journal of Bone and Joint

摘　　要：抗血管生成的酪氨酸激酶抑制剂(anti-angiogenesis tyrosine kinase inhibitors,AA-TKIs)目前认为是骨与软组织肉瘤的一线或者二线治疗[1-4],并且随着各种临床试验的开展,进一步被用于新辅助治疗或者是联合治疗。For the treatment of bone and soft tissue sarcoma,anti-angiogenesis tyrosine kinase inhibitors(AA-TKIs)in combination with immune checkpoint inhibitor(ICIs)has seemed to prolong progression-free survival,overcome the secondary drug resistance and improve objective response rates than single AA-TKIs.Thus this combination has been applicated to clinical practice more frequently.Nevertheless,more toxicities have also emerged from the combination therapy,which starves for better surveillance,prevention,and management.In November 2021,the members of the Chinese Sarcoma Study Group conducted a thorough discussion on this issue and reached a consensus based on literature review,discussion of clinical cases as well as voting by ballot,focusing on the prophylaxis and treatment of common Adverse Events(AEs)that may occur during the combination use of AA-TKIs and ICIs.This article aims to improve our understanding and provide recommendations for prophylaxis and treatment of AEs during combination therapy so as to improve quality of life(QoL)and achieve optimal outcomes.

关 键 词：蛋白酪氨酸激酶类 免疫检查点抑制剂 血管生成抑制剂 生物学标记 药理学 

分 类 号：R738.1[医药卫生—肿瘤]